» Articles » PMID: 26219895

C14ORF166 Overexpression is Associated with Pelvic Lymph Node Metastasis and Poor Prognosis in Uterine Cervical Cancer

Overview
Journal Tumour Biol
Publisher Sage Publications
Specialty Oncology
Date 2015 Jul 30
PMID 26219895
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

C14ORF166 (chromosome 14 open reading frame 166) is a transcriptional repressor related to the regulation of centrosome architecture. However, the role of C14ORF166 in the development and progression of cancer remains largely unknown. The aim of this study was to investigate the expression and clinicopathological significance of C14ORF166 in cervical cancer. C14ORF166 expression was analyzed using quantitative real-time PCR (RT-PCR) and Western blotting in cervical cancer cell lines and eight paired cervical cancer samples and the adjacent normal tissues. Immunohistochemistry was used to analyze C14ORF166 protein expression in 148 clinicopathologically characterized cervical cancer specimens. Statistical analyses were performed to evaluate the relationship between the expression of C14ORF166 and clinicopathologic features and prognosis. C14ORF166 mRNA and protein expression were significantly upregulated in cervical cancer cell lines and tissue samples (P < 0.05). Immunohistochemical analysis revealed a high expression of C14ORF166 was observed in 39.9 % (59/148) of the cervical cancer specimens; the remaining samples expressed low levels or did not express any detectable C14ORF166. The chi-square test indicated that high-level expression of C14ORF166 was significantly associated with International Federation of Gynecology and Obstetrics (FIGO) stage (P < 0.001), vital status (P = 0.026), tumor size (P = 0.034), serum squamous cell carcinoma antigen level (SCC-Ag; P = 0.035), and pelvic lymph node metastasis (P < 0.001). Patients with highly expressed C14ORF166 showed a tendency to receive postoperative chemotherapy (P = 0.005) and postoperative radiation (P = 0.008). Furthermore, high C14ORF166 expression was associated with poorer overall survival compared to low C14ORF166 expression, and C14ORF166 was a significant prognostic factor in univariate and multivariate analysis (P < 0.05). High C14ORF166 expression had prognostic value for poor outcome in cervical cancer. C14ORF166 may represent a biomarker of pelvic lymph node metastasis and enable the identification of high-risk patients along with selection of appropriate treatment strategies.

Citing Articles

Study on the preoperative value of serum SCC-Ag in predicting the stromal invasion of cervical squamous cell carcinoma.

Qin L J Cancer Res Clin Oncol. 2023; 149(11):9167-9171.

PMID: 37184678 DOI: 10.1007/s00432-023-04836-6.


Development and validation of a nomogram for predicting pelvic lymph node metastasis and prognosis in patients with cervical cancer.

Wang M, Ma M, Yang L, Liang C Front Oncol. 2022; 12:952347.

PMID: 36119526 PMC: 9479219. DOI: 10.3389/fonc.2022.952347.


Assessment of p16 and Ki67 Immunohistochemistry Expression in Squamous Intraepithelial Lesion with Cytohistomorphological Correlation.

Ghosh A, M N, Padmanabha N, Kini H Iran J Pathol. 2020; 15(4):268-273.

PMID: 32944038 PMC: 7477676. DOI: 10.30699/ijp.2020.112421.2208.


Development and Validation of a Deep Learning Radiomics Model Predicting Lymph Node Status in Operable Cervical Cancer.

Dong T, Yang C, Cui B, Zhang T, Sun X, Song K Front Oncol. 2020; 10:464.

PMID: 32373511 PMC: 7179686. DOI: 10.3389/fonc.2020.00464.


LncRNA LINC01305 silencing inhibits cell epithelial-mesenchymal transition in cervical cancer by inhibiting TNXB-mediated PI3K/Akt signalling pathway.

Yan S, Chu D, Qiu H, Xie Y, Wang C, Zhang J J Cell Mol Med. 2019; 23(4):2656-2666.

PMID: 30697971 PMC: 6433725. DOI: 10.1111/jcmm.14161.


References
1.
Sturgeon C, Duffy M, Hofmann B, Lamerz R, Fritsche H, Gaarenstroom K . National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in liver, bladder, cervical, and gastric cancers. Clin Chem. 2010; 56(6):e1-48. DOI: 10.1373/clinchem.2009.133124. View

2.
Zhang L, Huang H, Zhang L, Hou T, Wu S, Huang Q . URG4 overexpression is correlated with cervical cancer progression and poor prognosis in patients with early-stage cervical cancer. BMC Cancer. 2014; 14:885. PMC: 4259088. DOI: 10.1186/1471-2407-14-885. View

3.
Parida S, Mandal M . Inflammation induced by human papillomavirus in cervical cancer and its implication in prevention. Eur J Cancer Prev. 2014; 23(5):432-48. DOI: 10.1097/CEJ.0000000000000023. View

4.
Noordhuis M, Fehrmann R, Wisman G, Nijhuis E, van Zanden J, Moerland P . Involvement of the TGF-beta and beta-catenin pathways in pelvic lymph node metastasis in early-stage cervical cancer. Clin Cancer Res. 2011; 17(6):1317-30. DOI: 10.1158/1078-0432.CCR-10-2320. View

5.
Yu H, Pardoll D, Jove R . STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer. 2009; 9(11):798-809. PMC: 4856025. DOI: 10.1038/nrc2734. View